PEAK6
MDGL icon

PEAK6’s Madrigal Pharmaceuticals MDGL Stock Holding History

PEAK6’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-400
Closed -$209K – 3039
2026
Q1 		$209K Hold
400
– – ﹤0.01% 2266
2025
Q4 		$233K Buy
+400
New +$204K ﹤0.01% 2345
2025
Q1 		– Sell
-7,500
Closed -$2.31M – 3367
2024
Q4 		$2.31M Buy
+7,500
New +$2.11M ﹤0.01% 1329

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PEAK6's MDGL Position: Q2 2026 in Review

PEAK6 increased its Madrigal Pharmaceuticals (MDGL) stake by 17,750% in Q2 2026, buying an estimated $182K and bringing the position to 357 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #2280.

PEAK6 first reported a position in MDGL in Q4 2024 and has held it in 4 quarters since. The position peaked at $710K in Q4 2024. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • PEAK6 held 357 shares of Madrigal Pharmaceuticals worth $192K as of Q2 2026.
  • PEAK6 bought 355 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $182K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of PEAK6's portfolio in Q2 2026, its #2280 holding.
  • PEAK6 first reported a position in Madrigal Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
  • PEAK6's Madrigal Pharmaceuticals position peaked at $710K in Q4 2024.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.